Analyst consensus rating
InspireMD Analyst Rating: Buy
NSPR is rated Buy by 3 analysts with a $3.33 target. As of 2026-08-24.
Direct answer
InspireMD's consensus rating is Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.33.
Forecast evidence checked August 24, 2026.
Get free InspireMD email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.90
- Average price target
- $3.33
- High price target
- $4.00
- Low price target
- $3.00
- Low target gap
- +233.4%
- Target upside
- +270.5%
- High target gap
- +344.5%
- Target range width
- 111.1%
- Consensus rating
- Buy
- Analysts
- 3
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for InspireMD?
InspireMD has a verified Buy consensus. The same dataset has an average price target of $3.33.
How far are InspireMD's low and high targets from the recorded price?
The low target implies +233.4%, while the high target implies +344.5%.
How many analysts are included in InspireMD's consensus?
The verified consensus includes 3 analysts.
How is InspireMD's target upside or downside calculated?
The average target of $3.33 is divided by the recorded price of $0.90, then one is subtracted to produce +270.5%. This does not guarantee a future return.
When was InspireMD's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.